Pages that link to "Q36720978"
Jump to navigation
Jump to search
The following pages link to Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine (Q36720978):
Displaying 50 items.
- Design and pre-clinical evaluation of a universal HIV-1 vaccine (Q21092234) (← links)
- Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients (Q24602593) (← links)
- Synthetic DNA vaccine strategies against persistent viral infections (Q27016078) (← links)
- Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes (Q27304342) (← links)
- Increased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA Vaccine (Q27485003) (← links)
- Sang Froid in a time of trouble: is a vaccine against HIV possible? (Q27487961) (← links)
- A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial (Q27488963) (← links)
- Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity (Q27646554) (← links)
- Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults (Q28740321) (← links)
- A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204) (Q28741673) (← links)
- In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers (Q28744555) (← links)
- Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses (Q28749120) (← links)
- Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa (Q28749224) (← links)
- Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. (Q30369679) (← links)
- Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). (Q30379200) (← links)
- Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review (Q30404393) (← links)
- Human immunodeficiency virus vaccine trials (Q30424366) (← links)
- Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine (Q30578618) (← links)
- Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection (Q30982732) (← links)
- Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine (Q33527383) (← links)
- Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccine (Q33614476) (← links)
- HIV-1 vaccine development after STEP. (Q33642318) (← links)
- Identifying Stabilizers of Plasmid DNA for Pharmaceutical Use (Q33673230) (← links)
- Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit (Q33698152) (← links)
- Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054) (Q33737476) (← links)
- Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate (Q33749950) (← links)
- DNA vaccines: developing new strategies against cancer (Q33756622) (← links)
- Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. (Q33875160) (← links)
- HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission (Q33936741) (← links)
- Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial (Q34023588) (← links)
- The influence of delivery vectors on HIV vaccine efficacy (Q34077543) (← links)
- Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization (Q34099837) (← links)
- Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical trial (Q34263835) (← links)
- Genetic immunization in the lung induces potent local and systemic immune responses (Q34438559) (← links)
- The T-cell response to HIV. (Q34642996) (← links)
- Challenges in the development of an HIV-1 vaccine (Q34657290) (← links)
- DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial (Q34663554) (← links)
- DNA vaccines: ready for prime time? (Q34824179) (← links)
- A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial (Q34833926) (← links)
- Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance (Q34991038) (← links)
- Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial (Q35055198) (← links)
- Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system (Q35060140) (← links)
- A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component (Q35076748) (← links)
- Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011) (Q35118834) (← links)
- HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable (Q35234257) (← links)
- Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects (Q35567414) (← links)
- A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults (Q35593139) (← links)
- HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies (Q35728947) (← links)
- Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials (Q35762443) (← links)
- HIV DNA Vaccine: Stepwise Improvements Make a Difference (Q35826742) (← links)